On September 24, reporters from Dahe Finance learned through Major Pharmaceutical Holdings' official WeChat account that recently, the opening ceremony for Chongqing Pharmaceutical Group Jiulong Modern Traditional Chinese Medicine Co., Ltd. (hereinafter referred to as "Zhongyao Jiulong") was held in Nanchuan District, Chongqing City. Officials from relevant departments, including the Chongqing Economic and Information Commission, the Health Commission, and the Drug Administration, as well as leaders from the Nanchuan District Committee and District Government, attended the ceremony. Noteworthy attendees included Qiu Huaiwei, Secretary of the Party Committee and Chairman of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (hereinafter referred to as "China Resources Sanjiu"), and Yuan Quan, Secretary of the Party Committee and Chairman of Chongqing Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as "Zhongyao Group").

Zhongyao Jiulong was established in October 2020 through joint investment from Major Pharmaceutical Holdings' subsidiary, Zhongyao Group, and China Resources Sanjiu. The company primarily focuses on the production of traditional Chinese medicine formula granules, traditional Chinese medicinal pieces, medicinal herbs, and proprietary Chinese medicines. It is located in the Traditional Chinese Medicine Science and Technology Industrial Park in Daguang Town, Nanchuan District, covering an area of 131 acres, with a total investment of 400 million yuan. The project started construction on May 20, 2022, and the first phase of the project is now in operation, with an annual output value expected to reach 1.01 billion yuan.

Yuan Quan pointed out that Zhongyao Group ranks among the top tier of China's pharmaceutical commercial industry. As a benchmark enterprise in pharmaceutical manufacturing, China Resources Sanjiu's collaboration with Zhongyao Group to establish Zhongyao Jiulong represents an important exploration in the modernization of traditional Chinese medicine. Zhongyao Jiulong aims to position itself at a high-end in the entire traditional Chinese medicine industry chain, serve the local market in Nanchuan and Chongqing, and extend its influence nationwide. The company will continuously improve product quality and market competitiveness, centering its efforts on patient needs to contribute significantly to a healthy China.

Qiu Huaiwei expressed that China Resources Sanjiu will engage in broader and deeper cooperation with Zhongyao Group in the future, integrating its outstanding production and research technology with Zhongyao Group's advantages in market circulation. The goal is to fully align with China Resources Sanjiu's national procurement system, establish a "Distribution Center for Chongqing Hospital Formulations," and jointly promote intelligent manufacturing and transformation of market operations in traditional Chinese medicine.

Relevant departments at the Chongqing city level, along with the Nanchuan District government and other associated departments, stated that Chongqing is currently working diligently to create a “33618” industrial cluster system, continuously promoting the modernization of the traditional Chinese medicine industry. In the next steps, they plan to provide strong support for Zhongyao Jiulong from policy, industry, and channel perspectives, and to strengthen collaboration between enterprises and medical institutions, as well as between academia and research. The aim is to create a distinctive Chongqing traditional Chinese medicine brand with unique characteristics from Nanchuan.

https://finance.eastmoney.com/a/202409253189843491.html